Asset Details
Do you wish to reserve the book?
Critical Variables Affecting Clinical-Grade Production of the Self-Inactivating Gamma-Retroviral Vector for the Treatment of X-linked Severe Combined Immunodeficiency
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Critical Variables Affecting Clinical-Grade Production of the Self-Inactivating Gamma-Retroviral Vector for the Treatment of X-linked Severe Combined Immunodeficiency
Do you wish to request the book?
Critical Variables Affecting Clinical-Grade Production of the Self-Inactivating Gamma-Retroviral Vector for the Treatment of X-linked Severe Combined Immunodeficiency
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Critical Variables Affecting Clinical-Grade Production of the Self-Inactivating Gamma-Retroviral Vector for the Treatment of X-linked Severe Combined Immunodeficiency
2012
Overview
In two earlier trials, patients with X-linked Severe Combined Immune Deficiency (SCID-X1) were successfully cured following gene therapy with a gamma-retroviral vector (gRV) expressing the common gamma chain of the interleukin-2 receptor (IL2RG). We have previously demonstrated that GMP-grade SIN gRV can be produced at high titers using transient transfection in bioreactors (van der Loo et al, Gene Ther 2011). Herein we report on the large-scale production of a clinical-grade SIN IL2RG gRV pseudotyped with the Gibbon Ape Leukemia Virus envelope for a new gene therapy trial for SCID-X1, and highlight variables that were found to be critical for transfection-based large-scale SIN gRV production. The vector was certified and released for treatment of SCID-X1 in a multi-center international phase I/II trial which is currently recruiting patients in Paris, London, Los Angeles, Boston and Cincinnati.
Subject
